MERCK & CO., INC.

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; CMMI Proposed Accelerated Approval Payment Policy; CMMI Medicaid Proposed Rebate Rule.

Issues related to appropriations and federal health programs; reimbursement issues; H.R.9027/S.4690, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025; H.R.9029/S.4942, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025.

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, antimicrobial resistance legislation, and VICP Program; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; S.1355, PASTEUR Act of 2023; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.

Issues related to pharmaceutical IP and supply chain.